HIF1α and HIF2α independently activate SRC to promote melanoma metastases by Hanna, Sara C. et al.
Research article
2078 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 5   May 2013
HIF1α and HIF2α independently activate SRC 
to promote melanoma metastases
Sara C. Hanna,1 Bhavani Krishnan,1 Sean T. Bailey,1 Stergios J. Moschos,1 Pei-Fen Kuan,1,2  
Takeshi Shimamura,3 Lukas D. Osborne,4 Marni B. Siegel,1 Lyn M. Duncan,5 E. Tim O’Brien III,4 
Richard Superfine,4 C. Ryan Miller,1,6 M. Celeste Simon,7 Kwok-Kin Wong,8,9 and William Y. Kim1
1Lineberger Comprehensive Cancer Center and 2Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 
3Oncology Institute, Department of Molecular Pharmacology and Therapeutics, Loyola University Chicago, Maywood, Illinois, USA.  
4Department of Physics and Astronomy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.  
5Pathology Service and Dermatopathology Unit, Massachusetts General Hospital, Boston, Massachusetts, USA.  
6Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.  
7Abramson Family Cancer Research Institute, Department of Cancer Biology, Department of Cell and Developmental Biology,  
Howard Hughes Medical Institute, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 8Department of Medicine, Harvard Medical School,  
Department of Medical Oncology and Lowe Center for Thoracic Oncology Dana-Farber/Harvard Cancer Center, Boston, Massachusetts, USA.  
9Ludwig Center at Dana-Farber/Harvard Cancer Center, Boston, Massachusetts, USA.
Malignant melanoma is characterized by a propensity for early lymphatic and hematogenous spread. The 
hypoxia-inducible factor (HIF) family of transcription factors is upregulated in melanoma by key oncogen-
ic drivers. HIFs promote the activation of genes involved in cancer initiation, progression, and metastases. 
Hypoxia has been shown to enhance the invasiveness and metastatic potential of tumor cells by regulating the 
genes involved in the breakdown of the ECM as well as genes that control motility and adhesion of tumor cells. 
Using a Pten-deficient, Braf-mutant genetically engineered mouse model of melanoma, we demonstrated that 
inactivation of HIF1α or HIF2α abrogates metastasis without affecting primary tumor formation. HIF1α and 
HIF2α drive melanoma invasion and invadopodia formation through PDGFRα and focal adhesion kinase–
mediated (FAK-mediated) activation of SRC and by coordinating ECM degradation via MT1-MMP and MMP2 
expression. These results establish the importance of HIFs in melanoma progression and demonstrate that 
HIF1α and HIF2α activate independent transcriptional programs that promote metastasis by coordinately 
regulating cell invasion and ECM remodeling.
Introduction
Melanoma is one of the most lethal forms of skin cancer and is 
increasing in incidence (1). Early stage melanomas are highly cur-
able by surgical resection, and adjuvant therapy is rarely necessary. 
However, patients with later stage melanomas that have progressed 
to metastasis have a much lower chance of long-term survival (2).
Hypoxia-inducible factor (HIF) is a heterodimeric transcription 
factor composed of an α and a β subunit. There are 3 α subunit 
genes: HIF1α, HIF2α, and HIF3α, which partner with a β subunit 
HIFβ (also known as the arylhydrocarbon nuclear translocator, 
ARNT) to form a transcriptionally active complex. HIFα subunits 
are posttranslationally hydroxylated on conserved prolyl residues in 
an oxygen-dependent manner and then degraded by the von Hippel–
Lindau (pVHL) E3 ubiquitin ligase complex, while HIFβ subunits are 
constitutively stable. Therefore, HIFα subunits are stabilized under 
hypoxia but degraded under conditions of normoxia (3, 4).
HIF regulates genes that would be predicted to be protumori-
genic, including genes involved in adaptation to an unfavorable 
tumor microenvironment. For example, HIF activates proangio-
genic genes, such as VEGFA, PDGFB, and IL-8, genes that regulate 
cellular pH, such as carbonic anhydrase 9 (CA9), and genes that 
regulate glycolytic cellular metabolism, such as lactate dehydro-
genase A (LDHA) and phosphofructokinase (PFK) (4, 5). While the 
majority of transcriptional targets of HIF1α and HIF2α are over-
lapping, it is now clear that HIF1α and HIF2α have unique target 
genes as well. For example HIF1α specifically regulates multiple 
genes involved in glycolysis, while HIF2α–specific targets include 
OCT4 and cyclin D1 (CCND1) among others (6–9).
Hypoxia has been shown to enhance the invasiveness and meta-
static capacity of tumor cells and is critical for placental develop-
ment, a process that requires invasion of the maternal decidua by 
trophoblast cells (10–13). HIF activation plays a key role in these 
processes through transcriptional regulation of the following 
kinds of genes: genes involved in breakdown of the ECM, such as 
MMPs; genes that are involved in the epithelial-to-mesenchymal 
transition (EMT), such as E-Cadherin (CDH1) and N-Cadherin 
(CDH2); genes that promote metastases, such as TWIST1 and lysyl 
oxidase (LOX); and genes implicated in motility, adhesion, and 
invasion, such as MET/HGF, CXCR4/SDF-1, and αV (ITGAV) β3 
(ITGB3) integrin (4, 5, 13).
Both HIF1α and HIF2α have been shown to be overexpressed 
in melanoma (14). The dermal-epidermal junction where melano-
cytes reside is relatively hypoxic, and HIF1α is necessary for the 
AKT-mediated transformation of melanocytes (15). HIF activation 
is a consequence of several of the signature genetic events found 
in melanoma. For example, HIF is upregulated by mutated Ras 
and Braf as well as loss-of-function mutations of PTEN (16–19). In 
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addition, HIF appears to mediate a prosurvival signaling pathway 
downstream of the microphthalmia transcription factor (MITF) 
(20), but has also been reported to downregulate MITF expression, 
suggesting a possible negative feedback loop (21, 22). Based on 
these observations, we sought to directly explore the contributions 
of HIFs to melanoma pathogenesis. To this end, we studied the 
impact of Hif1α or Hif2α inactivation on invasion and metasta-
ses in vitro as well as in an autochthonous, genetically engineered 
mouse (GEM) model of melanoma.
Results
Inactivation of Hif1α or Hif2α does not affect the initiation or progression 
of Braf-activated, Pten-deficient melanomas. For this study, we utilized 
a previously characterized conditional mouse model of melanoma 
based on melanocyte-specific Pten inactivation and BrafV600E activa-
tion (hereafter called Pten;Braf) (23). In this model, temporal and 
spatial expression of Cre recombinase is controlled by tamoxifen 
and the tyrosinase promoter, respectively. Genetic recombina-
tion of floxed alleles therefore occurs in tyrosinase-positive cells 
exposed to 4-hydroxytamoxifen (4-OHT), giving rise to melano-
mas that are highly metastatic to regional lymph nodes (23).
To determine whether Hif1α or Hif2α plays an active role in mel-
anoma initiation and progression, we intercrossed Pten;Braf mice 
with mice harboring conditional knockout alleles of Hif1α and 
Hif2α (Hif1L/L, hereafter called Hif1, and Hif2L/L, hereafter called 
Hif2) to generate cohorts of (a) Pten;Braf;Hif1, (b) Pten;Braf;Hif2, and 
(c) Pten;Braf control mice. At 6 weeks of age, mice from the above 
cohorts were treated with topical 4-OHT at the base of the tail to 
induce recombination of the floxed alleles and initiate tumorigen-
esis. Pigmented lesions, limited to the site of 4-OHT application, 
began to appear approximately 3 weeks later (Supplemental Fig-
ure 1A; supplemental material available online with this article; 
doi:10.1172/JCI66715DS1). Upon tumor formation, validation 
of Hif1α or Hif2α loss was confirmed by Western blot of tumor 
lysates (Supplemental Figure 1B). However, neither inactivation 
of Hif1α nor of Hif2α appeared to affect melanoma pigmentation 
grossly (Figure 1A), their growth rate relative to control Pten;Braf 
tumors (Supplemental Figure 1C), or the percentage of mice living 
(mice were sacrificed secondary to primary tumor burden) (Figure 
1B). Moreover, inactivation of Hif1α or Hif2α in Pten;Braf mela-
nomas did not appear to alter the tumor-free survival of the mice 
harboring these tumors (Supplemental Figure 1D) nor the weight 
of the tumor itself (Supplemental Figure 1E). In aggregate, these 
data suggest that Hif1α and Hif2α are dispensable for the initia-
tion and progression of Pten;Braf melanomas.
Histological analysis confirmed that inactivation of Hif1α or 
Hif2α in Pten;Braf melanomas did not appreciably alter their pig-
mentation and that the tumors were virtually indistinguishable 
(Figure 1A). The melanomas continued to have a dense stroma and 
reside at the epidermal-dermal junction consistent with previous 
observations (23). Constitutive expression of Hif1α and Hif2α 
(due to inactivation of pVHL) is intimately associated with the 
pathogenesis of renal cell carcinoma (RCC), and in this context 
as well as that of other solid tumors, Hif1α and Hif2α activation 
potently stimulates angiogenesis (4, 24). We therefore also exam-
ined the effects of Hif1α or Hif2α inactivation on the vascularity of 
Pten;Braf melanomas. Loss of Hif1α or Hif2α decreased melanoma 
vascularity (as assessed by the number of CD31+ microvessels per 
high powered field) of Pten;Braf;Hif1 and Pten;Braf;Hif2 melanomas 
relative to Pten;Braf controls (Supplemental Figure 1, F and G). 
Thus, while Hif1α and Hif2α regulate melanoma angiogenesis, 
this did not have an impact on melanoma growth.
HIF1α and HIF2α expression are increased in melanoma metasta-
ses and their inactivation abrogates lymph node metastases of Pten;Braf 
melanomas. Both expression of HIF and tumor hypoxia correlate 
with an increased rate of metastases in many tumor types (11, 19). 
We therefore hypothesized that, while Hif1α and Hif2α do not 
play prominent roles in melanoma initiation or progression, they 
might have an impact on its metastatic capacity.
To explore this possibility, tissue microarrays (TMAs) spotted 
with nevi, thin (Breslow thickness of invasion ≤ 2 mm) and thick 
primary melanomas, and melanoma metastases were stained with 
antibodies specific to HIF1α and HIF2α and scored in a blind-
ed fashion (Figure 1, C and D). While HIF1α had a progressive 
increase in expression from nevus to metastasis, HIF2α expression 
was more variable, with the high levels of expression seen in thick 
primary melanomas as well as metastases.
Examination of the regional lymph nodes in Pten;Braf mice 
revealed significant areas of pigmentation (Figure 1E, gross) as pre-
viously described in this model (23). In contrast, the locoregional 
lymph nodes from mice harboring Pten;Braf;Hif1 and Pten;Braf;Hif2 
melanomas either had markedly fewer foci or completely lacked 
visible pigmentation, suggesting that deletion of Hif1α or Hif2α 
may abrogate lymph node metastases.
Histologic examination of the lymph nodes from mice harbor-
ing Pten;Braf melanomas confirmed the presence of clusters of 
melanin pigment–positive melanoma cells in the subcapsular 
sinuses of lymph nodes, indicative of melanoma metastases (Fig-
ure 1E, ×10 and ×20). However, examination of lymph nodes from 
Pten;Braf;Hif1 and Pten;Braf;Hif2 mice showed a relative absence of 
these melanotic foci. Quantification of lymph node metastases 
revealed that mice with Pten;Braf melanomas had a significantly 
higher percentage of lymph node metastases than mice harbor-
ing Pten;Braf;Hif1 and Pten;Braf;Hif2 melanomas (Figure 1F) as well 
as a higher percentage of melanin per lymph node (Supplemen-
tal Figure 1H). Detailed histologic assessment confirmed that 
HIF deficiency did not simply result in loss of pigmentation in 
the metastasis or result in a different pattern of metastatic spread. 
Therefore, Hif1α and Hif2α are required for lymphatic metastases 
in Pten;Braf melanomas.
Hypoxia enhances melanoma cell invasion and invadopodia formation. 
Previous work has shown that melanoma cell lines expressing 
mutant BRAFV600E express detectable levels of HIF1α under nor-
moxia (16). We wished to examine HIF1α or HIF2α expression 
in human melanoma cells in comparison with human neonatal 
foreskin melanocytes under conditions of normoxia or hypoxia. 
To this end, a panel of BRAFV600E mutant melanoma cell lines or 
nontransformed melanocytes was cultured in normoxia (21% 
O2) or hypoxia (1% O2) overnight. Whole-cell extracts were then 
immunoblotted for HIF1α or HIF2α (Figure 2A). Most melano-
ma cell lines displayed variable levels of both HIF1α and HIF2α 
in hypoxia. While there were detectable levels of HIF1α in cells 
cultured under normoxia (Supplemental Figure 2), they were sig-
nificantly lower than those found in hypoxia, and we did not see 
appreciable levels of normoxic HIF2α.
Hypoxia reportedly increases the invasiveness of cancer cells and 
trophoblast stem cells (TS cells) in certain physiologic contexts 
in vitro. This hypoxia-induced invasion is reduced by deletion 
of ARNT or coinactivation of Hif1α and Hif2α (13). However, 
whether inactivation of HIF1α or HIF2α alone was sufficient to 
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Figure 1
Inactivation of Hif1α or Hif2α does not affect initiation of the survival or growth of Pten;Braf melanomas, but abrogates lymph node metastases. 
(A) Representative gross images as well as low- and high-power photomicrographs of H&E-stained Pten;Braf, Pten;Braf;Hif1, and Pten;Braf;Hif2 
melanomas taken at gross, ×10, and ×20 magnification. (B) Kaplan-Meier survival curve of cohorts of mice of the indicated genotypes (Pten;Braf, 
n = 39; Pten;Braf;Hif1, n = 20; and Pten;Braf;Hif2, n = 28). P = 0.6585, log-rank test. (C and D) TMA analysis of HIF1α and HIF2α expression in 
melanocytic lesions. (E and F) Representative gross images, low- and high-power photomicrographs, and quantification of lymph node metasta-
ses from the indicated genotypes Pten;Braf (27/39), Pten;Braf;Hif1 (2/13), and Pten;Braf;Hif2 (4/15) taken at gross, ×10, and ×20 magnification. 
Error bars show SEM. ***P < 0.0005; **P < 0.005; *P < 0.05.
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decrease invasion was not examined. We first wanted to confirm 
that hypoxia could induce the invasion of melanoma cells through 
Matrigel. To this end, A375 SM and WM2664 cells were allowed 
to invade a Matrigel chamber under both normoxia and hypoxia. 
Hypoxia significantly increased the number of cells invading 
the Matrigel chamber in both cell lines (Figure 2, B and C) and 
also appeared to increase melanoma cell motility (Supplemental 
Figure 3, A and B) in an in vitro wound closure assay. Therefore, 
consistent with previously published results in other tumor types, 
hypoxia increases cell motility and invasion of melanoma cells.
Invadopodia are dynamic, actin-rich protrusions of the cellular 
membrane that are points of both ECM degradation and attach-
Figure 2
Hypoxia enhances melanoma cell inva-
sion and invadopodia formation. (A) 
The indicated cell lines were cultured in 
normoxia (N) (21% O2) or hypoxia (Hy) 
(1% O2) overnight. Whole-cell extracts 
were immunoblotted with the indicated 
antibodies. (B) Representative photo-
micrographs of A375 SM and WM2664 
cells that have invaded through Matri-
gel chambers. Original magnification, 
×10. (C) Quantification of A375 SM 
and WM2664 cells that have invaded 
through Matrigel chambers. (D) Repre-
sentative immunofluorescence images 
of A375 SM cells plated on Alexa Fluor 
568–conjugated fibronectin and stained 
with the indicated antibodies. Invadopo-
dia were defined as colocalization of 
cortactin, F-actin (phalloidin), and deg-
radation of Alexa Fluor 568 fibronectin 
and are indicated with yellow arrow-
heads. Original magnification, ×63. (E) 
Quantification of the percentage of cells 
with active invadopodia in A375 SM 
and WM2664 cells cultured overnight 
in normoxia or hypoxia. (F) Quantifica-
tion of the number of invadopodia per 
cell in A375 SM and WM2664 cells cul-
tured overnight in normoxia or hypoxia. 
Error bars show SEM. ****P < 0.0001; 
***P < 0.0005; *P < 0.05.
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ment (25). Invadopodia coordinate ECM degradation with cell 
motility and correlate highly with cancer cell invasiveness. Given 
this relationship between invadopodia and tumor cell invasion, 
we determined whether hypoxia could induce invadopodia for-
mation in melanoma cell lines. A375 SM and WM2664 cells were 
plated on Alexa Fluor 568–labeled fibronectin (artificial ECM) 
and allowed to form invadopodia in either normoxia or hypoxia 
overnight. Melanoma cells cultured under hypoxia had signifi-
cantly more cells with active invadopodia (defined as colocaliza-
tion of F-actin [phalloidin staining] and cortactin punctae with 
degradation of fibronectin) as well as a higher number of inva-
dopodia per cell (Figure 2, D–F). In aggregate, these data suggest 
that hypoxia promotes melanoma invasiveness as well as the for-
mation of active invadopodia.
Hypoxia-induced invasion and invadopodia formation are dependent 
upon HIF1α or HIF2α. We next asked whether either HIF1α or 
HIF2α was necessary for hypoxia-induced invasion and invadopo-
dia formation of melanoma cell lines. siRNAs directed to HIF1α 
and HIF2α were effective and specific at knocking down HIF1α 
and HIF2α in A375 SM and WM2664 cells cultured in hypoxia 
(Figure 3A). While HIF1α or HIF2α knockdown did not apprecia-
bly affect cell proliferation or survival, they both affected multiple 
parameters of cell motility and invasion relative to cells expressing 
nonspecific siRNAs. These included decreases in cellular migra-
tion under hypoxia (Supplemental Figure 3, C and D) but not nor-
moxia (Supplemental Figure 3, E and F), Matrigel invasion (Figure 
3, B and C, and Supplemental Figure 4, A and B), and invadopo-
dia formation (Figure 3, D and E, and Supplemental Figure 4C). 
Therefore, the increased invasiveness and numbers of invadopodia 
induced by hypoxia are both HIF1α and HIF2α dependent. Final-
ly, to assess the functional relevance of these in vitro outcomes, we 
stably silenced HIF1α or HIF2α and assessed these cells’ ability to 
form tumors upon tail-vein injection. shRNA to HIF1α or HIF2α 
significantly decreased the number of lung metastases after tail-
vein injection of A375 SM cells (Figure 3, F and G). Therefore, the 
in vitro decrease in motility, invasion, and invadopodia formation 
induced by silencing of HIF1α or HIF2α are reflected in in vivo 
metastatic tumor formation.
HIF1α and HIF2α upregulate PDGFRα and FAK and are necessary 
for hypoxia-induced SFK activation. Invadopodia were first described 
in chicken fibroblasts and were notably increased in fibroblasts 
transformed with viral-SRC (v-SRC) (25). It is now clear that 
SRC activation is a critical step in invadopodia formation. While 
various physiologic and pathogenic stimuli have been shown to 
upregulate SRC activity, only a few reports have examined whether 
hypoxia can result in SRC activation (26). We confirmed that SRC 
family kinases (SFK) could be activated by hypoxia by immuno-
blotting A375 SM and WM2664 cells with an antibody that rec-
ognizes phosphorylated Tyr416 within the activation loop of the 
cellular SRC (c-SRC) or its equivalent site on the other SFK mem-
bers (Lyn, Fyn, Lck, Yes, and Hck) (Figure 4A). In keeping with 
the notion that hypoxia-induced phosphorylation of SFKTyr416 is 
dependent upon HIF1α or HIF2α, knockdown of HIF1α or HIF2α 
under hypoxia or deletion of Hif1α or Hif2α in Pten;Braf melano-
mas significantly decreased levels of SFKTyr416 (Figure 4, B and C). 
Importantly, silencing of HIF1α or HIF2α did not appear to alter 
total SRC protein levels, suggesting that HIF1α and HIF2α RNAi 
were not merely decreasing total SRC expression, but were specifi-
cally regulating SRC activity (Figure 4, B and C).
Since HIF1α and HIF2α are transcription factors, we predicted 
that SFK activation is mediated through one or more of their 
transcriptional targets. In this regard, TWIST1, a well character-
ized HIF target gene, was recently shown to promote invadopodia 
formation and metastases via a PDGFRα-dependent upregulation 
of SFK in breast cancer cells (27–29). We therefore asked whether 
HIF1α and/or HIF2α regulate TWIST1 or PDGFRα in melanoma 
cells. We found that siRNA of HIF1α (but not HIF2α) specifically 
downregulated PDGFRA mRNA and protein levels under hypoxia 
in melanoma cell lines (Figure 4, B and D) and that inactivation 
of Hif1α (but not Hif2α) decreased Pdgfra mRNA expression in 
primary tumors (Supplemental Figure 5A). Unexpectedly, TWIST1 
expression was unaffected (Supplemental Figure 5, C and D).
Since our data indicate that HIF2α regulates pSFK through a 
pathway distinct from the HIF1α-PDGFRα axis, we examined 
whether HIF2α regulates expression of focal adhesion kinase (FAK), 
an activator of SRC (26). Correspondingly, siRNA of HIF2α (but not 
HIF1α) under hypoxia specifically downregulated both FAK mRNA 
and protein levels (Figure 4, B and E) and Fak mRNA expression 
was decreased in Pten;Braf melanomas with Hif2 inactivation (Sup-
plemental Figure 5B). Moreover, ChIP with antibodies specific to 
HIF1α and HIF2α demonstrated that both HIF1α and HIF2α were 
recruited to the promoter regions of PDGFRA and FAK in a hypoxia-
dependent manner (Supplemental Figure 5, E–H). At first approxi-
mation, this would seem contrary to the results showing that HIF1α 
and HIF2α specifically regulate PDGFRα and FAK. However, these 
results are in keeping with previous studies that have shown that 
recruitment of transcriptional coactivators rather than promoter 
occupancy determines HIF target gene specificity (30).
Finally, concurrent knockdown of HIF1α and HIF2α in the 
same cell resulted in an additive decrease of pSFK (Figure 4F) as 
well as Matrigel invasion (Figure 4, G–I). In aggregate, these data 
show that hypoxia activates SRC in a manner dependent upon 
both HIF1α and HIF2α, which act via parallel yet distinct signal-
ing programs involving PDGFRα and FAK, respectively.
Expression of stabilized HIF1α or HIF2α is sufficient to enhance nor-
moxic melanoma cell invasion, invadopodia, and reduce cell stiffness. 
While the above data suggest that HIF1α and HIF2α are necessary 
for hypoxia-dependent activation of SFK, invadopodia formation, 
Figure 3
Knockdown of HIF1α or HIF2α reduces the hypoxia-induced invasion 
and invadopodia formation of melanoma cell lines. (A) A375 SM and 
WM2664 cells were transfected with siRNAs against HIF1α, HIF2α, or a 
nonspecific sequence (NS). Whole-cell lysates were immunoblotted with 
the indicated antibodies. (B) Representative photomicrographs of A375 
SM and WM2664 cells transfected with the indicated siRNAs, which 
have invaded through Matrigel chambers under hypoxia. Original mag-
nification, ×10. (C) Quantification of A375 SM and WM2664 cells trans-
fected with the indicated siRNAs, which have invaded through Matrigel 
chambers under hypoxia. (D) Representative immunofluorescence 
images of siRNA-transfected A375 SM cells plated on Alexa Fluor 
568–conjugated fibronectin and stained with the indicated antibodies. 
Original magnification, ×63. Invadopodia were defined as colocalization 
of cortactin, F-actin (phalloidin), and degradation of Alexa Fluor 568 
fibronectin and are indicated with yellow arrowheads. (E) Quantification 
of the percentage of cells with active invadopodia in siRNA-transfected 
A375 SM and WM2664 cells. (F) Quantification of the number of visible 
lung metastases found in mice tail vein injected with A375 SM cells. 
(G) Gross representative images of the lungs from tail-vein–injected 
mice. Yellow arrows indicate lung metastases. Error bars show SEM. 
***P < 0.0005; **P < 0.005; *P < 0.05.
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and invasion, we wanted to determine whether HIF1α and HIF2α 
were sufficient to mediate these cellular signaling events and phe-
notypes. To this end we generated A375 SM and WM2664 cells 
expressing stabilized versions of HIF1α and HIF2α (HIF1dPA 
and HIF2dPA) that remain stable under normoxia (ref. 31 and 
Figure 5A). Importantly, the HIF1α- and HIF2α-expressing cells 
exhibited increases in melanoma cell line invasion (Figure 5, B 
and C) and invadopodia formation (Figure 5, D and E, and Sup-
plemental Figure 6). Additionally, HIF2dPA and to a lesser extent 
HIF1dPA were sufficient to increase pSFK levels (Figure 5F). The 
reduced potency of HIF1dPA may reflect the residual sensitivity 
of this isoform to proteasome inhibition and consequent lower 
levels of expression (6). Nonetheless, cells expressing HIF1dPA 
had increased levels of PDGFRα, while those expressing HIF2dPA 
had increased expression of FAK (Figure 5F), suggesting that 
expression of HIF1α and HIF2α are sufficient for the normoxic 
upregulation of PDGFRα and FAK respectively.
Previous work has identified physical properties such as cell 
stiffness as correlating with the invasive ability of cancer cells 
(32–34), and a variety of biophysical techniques including “mag-
netic tweezers” allow for measurements of cell stiffness in living 
cells. To determine whether the increased invasiveness associated 
with expression of stabilized HIF1α or HIF2α also correlated with 
alterations in cell compliance, fibronectin-conjugated magnetic 
beads were first allowed to associate with A375 SM cells express-
ing EGFP, HIF1dPA, or HIF2dPA, a magnetic pulse was then 
applied to each bead, and the resultant motion and recovery of 
the bead position were used to calculate cell stiffness (expressed 
in pascals [Pa]), as previously described (Figure 5G and ref. 33). An 
extracellular passive microrheology assay was also conducted and 
obtained measurements of cell stiffness that confirmed these find-
ings (Supplemental Figure 7, A and B; ref. 35). These results dem-
onstrate that not only are HIF1α and HIF2α sufficient to increase 
cell invasiveness, but they also significantly decrease cell stiffness.
HIF1α- and HIF2α-induced invasion is dependent on PDGFRα and 
FAK, respectively. In order to determine whether HIFα-induced 
invasion is dependent on PDGFRα or FAK, we assessed the effect 
of silencing PDGFRα or FAK on the invasive ability of A375 
SM and WM2664 cells expressing stabilized versions of HIF1α 
or HIF2α. To this end, we first verified efficient knockdown of 
PDGFRα or FAK in cells expressing stabilized HIF1α or HIF2α 
(Figure 6A). In keeping with the model that HIF1α and HIF2α 
specifically regulate PDGFRα and FAK, respectively, we saw that 
knockdown of PDGFRα resulted in decreased pSFK only in cells 
expressing stabilized HIF1α, while knockdown of FAK decreased 
pSFK in cells expressing stabilized HIF2α (Figure 6A). Moreover, 
consistent with the notion that HIF1α- and HIF2α-induced inva-
sion are specifically dependent upon PDGFRα and FAK, respec-
tively, knockdown of PDGFRα selectively inhibited the invasive 
ability of the melanoma cell lines expressing HIF1dPA (Figure 6, 
B–D), while knockdown of FAK only inhibited the invasive ability 
of the melanoma cell lines expressing HIF2dPA (Figure 6, B–D). In 
addition, consistent with the model that both HIF1α and HIF2α 
mediate their invasive effects via SRC, we noted that SRC inhi-
bition with dasatinib (100 nM) was sufficient to block the inva-
sion of A375 SM and WM2664 cells expressing stabilized HIF1α 
or HIF2α (Supplemental Figure 8, A–C). These data in aggregate 
demonstrate that PDGFRα is responsible for HIF1α-mediated 
invasion while HIF2α mediates invasion through FAK and that 
both HIF1α and HIF2α require SRC for invasion.
HIF1α and HIF2α regulate expression of MMPs implicated in invadopo-
dia formation. One of the primary features that distinguish invado-
podia from other plasma membrane protrusions such as filopodia 
or lamellipodia is the ability to degrade the ECM (25). This focal 
ECM degradation (primarily mediated by MMPs) allows the coor-
dinated destruction of the ECM with cellular motility and inva-
sion. In this regard, both a membrane-bound MMP, MT1-MMP 
(membrane type 1 MMP, also known as MMP14), and secreted 
MMPs, MMP2 and MMP9 colocalize with active invadopodia and 
are key determinants of invadopodia formation (25). We found 
that endogenous HIF1α was necessary for the hypoxic expression 
of MT1-MMP and that HIF1dPA could directly enhance normoxic 
MT1-MMP expression. In contrast, manipulations of HIF2α failed 
to alter MT1-MMP levels (Figure 7, A–C), but specifically regulated 
MMP2 expression (Figure 7, A, B, and D). Therefore, HIF1α and 
HIF2α not only regulate SRC activation, but also the expression of 
key MMPs involved in invadopodia-associated ECM degradation.
To address whether the regulation of MT1-MMP and MMP2 by 
HIF1α and HIF2α had a functional effect on melanoma invasion, 
we performed RNAi against MT1-MMP or MMP2 in our cell lines 
expressing stabilized HIF1α (HIF1dPA) and HIF2α (HIF2dPA) 
(Figure 7E). We had hypothesized that knockdown of MT1-MMP 
or MMP2 would decrease HIF1α- and HIF2α-mediated invasion, 
respectively. Unexpectedly, knockdown of either MT1-MMP or 
MMP2 resulted in a decrease of both HIF1α- and HIF2α-mediated 
invasion. (Figure 7, F–H). These results suggest that, while HIF1α 
and HIF2α are necessary and sufficient to regulate MT1-MMP 
and MMP2, respectively, the levels of MT1-MMP and MMP2 seen 
under normoxia (Figure 7B) are adequate to mediate invasion.
Knockdown of Hif1α and Hif2α reduces the hypoxia-induced invasion 
of cell lines derived from Pten;Braf murine melanomas. Collectively, our 
data demonstrate that HIF1α and HIF2α regulate a transcrip-
tional program of genes involved in the formation of active inva-
dopodia, cancer cell invasion, and cellular stiffness. To determine 
whether Hif1α and Hif2α behaved similarly in a defined genetic 
background, we generated cell lines from 2 independent Pten;Braf 
melanomas (2130 and 2460). The cells expressed Tryp1 protein 
(Supplemental Figure 9A) and had deletion of exons 4 and 5 of 
Figure 4
HIF1α and HIF2α upregulate PDGFRα and FAK and are necessary 
for hypoxia-induced SFK activation. (A) A375 SM and WM2664 cells 
were cultured in normoxia (21% O2) or hypoxia (1% O2) overnight. 
Whole-cell extracts were immunoblotted with the indicated antibod-
ies. (B) A375 SM and WM2664 cells were transfected with siRNAs 
against HIF1α, HIF2α, or a nonspecific sequence. Whole-cell lysates 
were immunoblotted with the indicated antibodies. (C) Tumor lysates 
from the indicated cohorts were immunoblotted for the indicated 
antibodies. (D and E) A375 SM and WM2664 cells were transfected 
with siRNAs against HIF1α, HIF2α, or a nonspecific sequence and 
cultured under hypoxia overnight. Total RNA was used to perform 
TaqMan quantitative real-time PCR for PDGFRA and FAK. (F) A375 
SM and WM2664 cells were transfected with siRNAs against HIF1α, 
HIF2α, both HIF1α and HIF2α, or a nonspecific sequence. Whole-cell 
lysates were immunoblotted with the indicated antibodies. (G) Rep-
resentative photomicrographs of A375 SM and WM2664 cells trans-
fected with the indicated siRNAs, which have invaded through Matri-
gel chambers. Original magnification, ×10. (H and I) Quantification of 
A375 SM and WM2664 cells transfected with the indicated siRNAs, 
which have invaded through Matrigel chambers. Error bars show SEM. 
***P < 0.0005; **P < 0.005; *P < 0.05.
research article
2086 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 5   May 2013
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 5   May 2013 2087
Pten (Supplemental Figure 9B), suggesting that they were derived 
from melanocyte lineage and had also undergone TyrCreERT2-
mediated recombination respectively.
Loss of PTEN and activation of BRAF are expected to result in 
increased levels of HIF1α as a consequence of PI3K and MEK/ERK 
upregulation, respectively (16–19). In keeping with this notion, we 
saw that pharmacologic inhibition of either BRAF or PI3K with 
vemurafenib and PIK90, respectively, downregulated not only 
HIF1α but also HIF2α levels (Figure 8A), suggesting that these 
oncogenic pathways contribute to the activation of HIF1α and 
HIF2α under conditions of hypoxia.
Finally, consistent with the findings in our human melanoma 
cell lines, hypoxia significantly increased the invasiveness of the 
Pten;Braf melanoma cell lines (2130 and 2460) through Matrigel 
(Figure 8, B and C). Moreover, knockdown of Hif1α and Hif2α was 
sufficient to decrease the hypoxic invasion of Pten;Braf melanoma 
cell lines (Figure 8, D–F). These results therefore substantiate 
the conclusion that Hif1α and Hif2α are necessary for hypoxia-
induced invasion in a defined genetic background of melanoma 
cell lines derived from murine Pten;Braf tumors.
Discussion
We found that while inactivation of Hif1α or Hif2α did not affect 
the initiation or progression of Pten;Braf melanomas, it signifi-
cantly reduced the incidence of lymphatic metastases (Figure 1F). 
Consistent with these findings, we show that HIF1α and HIF2α 
expression are increased in thick melanomas and metastases from 
patients and are both necessary and sufficient for the invasion 
and invadopodia formation of melanoma cell lines. Moreover, 
HIF1α and HIF2α activate distinct transcriptional programs that 
converge to activate SRC and coordinate ECM degradation via 
PDGFRα/MT1-MMP and FAK/MMP2, respectively. Finally, we 
demonstrate that hypoxia activates SRC and increases the inva-
siveness of cell lines derived from Pten;Braf melanomas and that 
hypoxia-induced invasion of these cells can be abrogated by knock-
down of Hif1α or Hif2α. Collectively, these findings demonstrate 
that, while HIF1α and HIF2α do not have an impact on primary 
melanoma initiation or progression, they promote melanoma cell 
invasion, invadopodia formation, and metastases through distinct 
yet convergent transcriptional programs.
Previous work examining the angiogenic profile of malignant 
melanomas shows that a significant percentage of human mela-
nomas express detectable levels of HIF1α and HIF2α by immuno-
histochemistry, but that only levels of HIF2α correlate with VEGF 
expression and a poor prognosis (14). Other work has confirmed 
that both mouse and human skin is relatively hypoxic and that, 
at least in the context of Ink4a/Arf-deficient mouse melanocytes, 
hypoxia and specifically stabilized HIF1α can cooperate with con-
stitutively active AKT in transformation (15). Whether HIF2α can 
mediate a similar effect was not determined. In our own studies, 
we stained a TMA from a large sample of patients with a spectrum 
of melanocytic lesions ranging from benign nevi to metastatic 
melanomas and showed that both HIF1α and HIF2α expression 
are increased in thick primary melanomas and metastases. In addi-
tion, we determined whether either loss of Hif1α or Hif2α affected 
the initiation of Pten;Braf melanomas in GEM models. We found 
that inactivation of Hif1α or Hif2α did not affect either tumor 
formation or the rate of melanoma growth after their formation. 
While there are distinct differences in the systems utilized (i.e., 
soft agar assays and xenografts versus an in vivo autochthonous 
model) as well as the genetic background of the cells (i.e., consti-
tutively activated Akt and Ink4a/Arf deletion versus Pten loss and 
mutant Braf activation), our results suggest that, at least in a GEM 
model of melanoma initiated by Pten loss and Braf activation, inac-
tivation of Hif1α or Hif2α did not appreciably affect melanocyte 
transformation or melanoma progression.
Our in vitro studies in both human melanoma cell lines and the 
cell lines derived from Pten;Braf murine melanomas suggest that 
HIF1α and HIF2α are critical nodes that mediate the hypoxia-
induced motility and invasiveness of melanoma cells. This work 
delineates the pathways activated by HIF1α and HIF2α that medi-
ate actin nucleation and ECM degradation at the forefront of 
invadopodia and shows for what we believe is the first time that 
HIF1α and HIF2α are necessary and sufficient for invadopodia 
formation. Notably, our data indicate what we believe to be a novel 
paradigm, that HIF1α and HIF2α act to promote a metastatic 
program through distinct pathways. Specifically, HIF1α induces 
SRC activity and ECM degradation via PDGFRα and MT1-MMP, 
while HIF2α signals to SRC via FAK and promotes ECM remodel-
ing through MMP2. Therefore, the transcriptional suite of genes 
activated by HIF1α and HIF2α in response to hypoxia coordinates 
the 2 processes that define invadopodia: (a) actin nucleation at cell 
membrane protrusions and (b) expression of proteases involved in 
the degradation of the ECM (25). Moreover, these HIF-dependent 
increases in invasion and invadopodia formation are accompa-
nied by decreases in cell stiffness, a physical property of cells that 
has been previously shown to inversely correlate with the invasive 
capacity of cells (32–34). Whether these HIF-induced alterations in 
cell compliance are a result of the same signaling pathways affect-
ing HIF-induced invasion has yet to be determined.
There are striking clinical similarities between malignant mela-
noma and RCC, including their hypervascularity and propensity 
for hemorrhagic central nervous system metastases, relative resis-
tance to radiation therapy, and, most intriguingly, their respon-
siveness to immunomodulatory agents such as IL-2, INF-α, and, 
Figure 5
Expression of stabilized HIF1α and HIF2α are sufficient to enhance 
normoxic melanoma cell invasion. (A) A375 SM and WM2664 cells 
were infected with retrovirus to stably express EGFP or stabilized ver-
sions of HIF1α (HIF1dPA) or HIF2α (HIF2dPA). Whole-cell extracts 
were immunoblotted with the indicated antibodies. (B) Representative 
photomicrographs of A375 SM and WM2664 cells stably expressing 
EGFP, HIF1dPA, or HIF2dPA, which have invaded through Matrigel 
chambers. Original magnification, ×10. (C) Quantification of A375 SM 
and WM2664 cells stably expressing EGFP, HIF1dPA, or HIF2dPA, 
which have invaded through Matrigel chambers. (D) Representative 
immunofluorescence images of A375 SM cells stably expressing 
EGFP, HIF1dPA, or HIF2dPA and plated on Alexa Fluor 568–conju-
gated fibronectin and stained with the indicated antibodies. Original 
magnification, ×63. Invadopodia were defined as colocalization of cor-
tactin, F-actin (phalloidin), and degradation of Alexa Fluor 568 fibronec-
tin and are indicated with yellow arrowheads. (E) Quantification of the 
percentage of cells with active invadopodia in A375 SM and WM2664 
cells stably expressing EGFP, HIF1dPA, or HIF2dPA. (F) Whole-cell 
extracts from A375 SM and WM2664 cells stably expressing EGFP, 
HIF1dPA, or HIF2dPA were immunoblotted with the indicated antibod-
ies. (G) A375 SM cells stably expressing EGFP, HIF1dPA, or HIF2dPA 
were allowed to adhere to fibronectin-conjugated magnetic beads and 
subjected to repeated magnetic pulses; the resultant motion and recov-
ery were quantified and used to calculate cell stiffness in Pascals (Pa). 
Error bars show SEM. ***P < 0.0005; **P < 0.005; *P < 0.05.
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of several of the signature genetic events found in melanoma. For 
example, loss-of-function mutations of PTEN result in an Akt-
dependent increase in mTOR activity and the translation of HIFα 
subunits (15, 18). HIF is also transcriptionally upregulated in 
tumors with mutant RAS and BRAF as well as in tumors overex-
pressing MITF (16–18, 20). Intriguingly, a recent report describes a 
most recently, antibodies directed at the T cell inhibitory ligand/
receptor complex PD-L1 and PD1 (36, 37). On a molecular level, 
HIF activation in the setting of pVHL inactivation is both necessary 
and sufficient for RCC tumorigenesis, and HIF appears to mediate 
the majority of phenotypes seen in the setting of VHL deficiency in 
mice (6, 31, 38, 39). Interestingly, HIF activation is a consequence 
Figure 6
HIF1α and HIF2α-dependent 
invasion require PDGFRα and 
FAK, respectively. (A) A375 
SM and WM2664 cells stably 
expressing EGFP, HIF1dPA, or 
HIF2dPA were transfected with 
siRNAs against PDGFRα and 
FAK. Whole-cell extracts were 
immuno blotted with the indicat-
ed antibodies. (B) Representa-
tive photomicrographs of A375 
SM and WM2664 cells stably 
expressing EGFP, HIF1dPA, or 
HIF2dPA and transfected with 
indicated siRNA oligos, which 
have invaded through Matri-
gel chambers. Original mag-
nification, ×10 magnification. 
(C) Quantification of A375 SM 
cells stably expressing EGFP, 
HIF1dPA, or HIF2dPA and trans-
fected with siRNA oligos against 
either PDGFRα or FAK, which 
have invaded through Matrigel 
chambers. (D) Quantification of 
WM2664 cells stably express-
ing EGFP, HIF1dPA, or HIF2d-
PA and transfected with siRNA 
oligos against either PDGFRα 
or FAK, which have invaded 
through Matrigel chambers. Error 
bars show SEM. ***P < 0.0005; 
**P < 0.005.
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Figure 7
HIF1α and HIF2α regulate expression of MMPs implicated in invadopodia formation. (A) A375 SM and 
WM2664 cells were transfected with siRNAs against HIF1α, HIF2α, or a nonspecific sequence. Whole-cell 
lysates were immunoblotted with the indicated antibodies. (B) A375 SM and WM2664 cells were infected 
with retrovirus to stably express EGFP or stabilized versions of HIF1α (HIF1dPA) or HIF2α (HIF2dPA). 
Whole-cell extracts were immunoblotted with the indicated antibodies. (C and D) A375 SM and WM2664 
cells were transfected with siRNAs against HIF1α, HIF2α, or a nonspecific sequence. Total RNA was used 
to perform TaqMan quantitative real-time PCR for MT1-MMP and MMP2. (E) A375 SM cells stably express-
ing HIF1dPA and HIF2dPA were transfected with siRNAs against MT1-MMP, MMP2, or a nonspecific 
sequences. Whole-cell lysate was immunoblotted with the indicated antibodies. (F) Representative photo-
micrographs of A375 SM and WM2664 cells stably expressing EGFP, HIF1dPA, or HIF2dPA and transfect-
ed with siRNA oligos against either MT1-MMP or MMP2, which have invaded through Matrigel chambers. 
Original magnification, ×10. (G and H) Quantification of A375 SM and WM2664 cells stably expressing 
EGFP, HIF1dPA, or HIF2dPA and transfected with siRNA oligos against MT1-MMP or MMP2, which have 
invaded through Matrigel chambers. Error bars show SEM. ***P < 0.0005; **P < 0.005; *P < 0.05.
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are kinases and are targetable by inhibitors; indeed, inhibitors 
against PDGFRα (imatinib) and SRC (dasatinib) are already FDA 
approved and are in use for the treatment of multiple cancers. Our 
results imply that PDGFRα, FAK, or SRC inhibition in early stage 
melanoma patients may be beneficial, as these pathways are criti-
cal for hypoxia-induced melanoma cell intravasation. However, 
whether activation of these pathways remains necessary for the 
maintenance of established metastases remains to be determined.
In summary, our results establish that HIF plays an active role 
in the metastatic progression of melanoma and demonstrate 
that HIF1α and HIF2α activate independent transcriptional 
programs, which induce invadopodia formation and invasion 
rare germline MITF mutation that predisposes to the development 
of melanoma, RCC, or both (40). Perhaps most interestingly, this 
MITF mutation, Mi-E318K, prevents its SUMOylation, enhances 
its chromatin occupancy, and appears to upregulate expression of 
genes involved in melanomagenesis and HIF1α (potential effects 
on HIF2α have yet to be reported). Therefore, the germline MITF 
mutation, Mi-E318K, appears to link two seemingly similar cancers 
on a molecular level, possibly through activation of HIF.
Hypoxia is associated with metastasis in many solid tumors, 
including melanoma. The data presented here suggest that 
HIF1α and HIF2α contribute to hypoxia-mediated metastatic 
spread through the pathways presented. PDGFRα, FAK, and SRC 
Figure 8
Knockdown of Hif1α and Hif2α reduces the hypoxia-induced invasion of cell lines derived from Pten;Braf melanomas. (A) 2460 Pten;Braf mela-
noma cells were treated with the indicated doses of vemurafenib, PIK-90, or DMSO overnight. Whole-cell lysates were immunoblotted with the 
indicated antibodies. (B) Representative photomicrographs of 2130 and 2460 Pten;Braf melanoma cells, which have invaded through Matrigel 
chambers under hypoxia or normoxia. Original magnification, ×10. (C) Quantification of 2130 and 2460 Pten;Braf melanoma cells, which have 
invaded through Matrigel chambers. (D) 2130 and 2460 Pten;Braf melanoma cells were transfected with siRNAs against murine Hif1α or Hif2α 
and immunoblotted with the indicated antibodies. (E) Representative photomicrographs of 2130 and 2460 Pten;Braf melanoma cells that were 
transfected with siRNAs against murine Hif1α or Hif2α and allowed to invade through Matrigel chambers under hypoxia. Original magnification, 
×10. (F) Quantification of 2130 and 2460 Pten;Braf melanoma cells that were transfected with siRNAs against murine Hif1α or Hif2α and allowed 
to invade through Matrigel chambers under hypoxia. Error bars show SEM. ***P < 0.0005;**P < 0.005; *P < 0.05.
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 5   May 2013 2091
(Supplemental Table 2). Proteins were visualized with an enhanced chemi-
luminescence system from Amersham using horseradish peroxidase–con-
jugated anti-rabbit or anti-mouse secondary antibody (Thermo-Scientific).
Matrigel invasion
Melanoma cell lines were plated in serum-free medium overnight. Then 
either 50,000 or 100,000 cells were seeded into an 8-μm Matrigel cham-
ber (BD Biosciences) with medium containing 10% FBS in the well. Cells 
were allowed to invade for 18–36 hours. Cells that had invaded through the 
Matrigel were then stained with the Siemens Staining Kit according to man-
ufacturer’s directions. Matrigel wells were then placed on a glass slide and 
analyzed and photographed using an Olympus IX51 microscope. Represen-
tative pictures were taken of each Matrigel well quadrant, and the number 
of cells that had invaded into the Matrigel was determined using ImageJ.
Invadopodia labeling and immunofluorescence
Active invadopodia were defined as colocalization of F-actin (phalloidin 
staining), cortactin, and degradation of fibronectin. Immunofluorescence 
microscopy was used to visualize the following: human fibronectin (BD 
Biosciences) was coupled to Alexa Fluor 568 using a protein-labeling kit 
(A10238; Molecular Probes). A 50-μg/ml solution was prepared in PBS 
and incubated on cross-linked gelatin (300 Bloom; Sigma-Aldrich) on 
glass coverslips. Cells were seeded onto coverslips, incubated for 18–24 
hours, fixed in 4% paraformaldehyde for 20 minutes, permeabilized in 
PBS containing 0.5% Triton X-100 for 5 minutes, blocked in PBS contain-
ing 3% BSA for 1 hour, and then incubated with phalloidin (indicator 
of F actin) or antibody specific to cortactin for 2 hours. Samples were 
then incubated with fluorophore-conjugated secondary antibodies for 
1 hour. Finally, coverslips were mounted with FluorSave reagent (Calbio-
chem). Experiments were observed using a LSM 710 laser scanning confo-
cal microscope (Carl Zeiss), and images were processed using Photoshop 
software (Adobe Systems) and ImageJ.
Mouse colony and treatment
Animals were generated and genotyped as previously described (23) and 
were in a mixed background. To generate focal tumors, 6-week-old animals 
were treated with 1 μl of 20 mM 4-OH tamoxifen (H7904; Sigma-Aldrich) at 
the base of their tails. Tumor growth and survival were assessed 3 times per 
week by caliper measurements of tumor areas (width2 × length)/2 [mm2]. 
Mice were sacrificed once the tumor had reached a volume of 1.2 cm3.
Mouse melanoma cell line generation
To generate mouse tumor cell lines, tumor samples were washed in PBS 
containing 20% penicillin/streptomycin and then dissociated in 5 ml of 
0.25% trypsin for 15 minutes at 37°C. Samples were then collected with 
10 ml of RPMI 1640 with 10% FBS and penicillin/streptomycin in a 15-ml 
conical tube and were allowed to settle for 15 minutes at room tempera-
ture. The resulting supernatant and pellet were plated on separate 10-cm 
plates. Medium was changed every 3 days. In order to eliminate fibroblast 
contamination, samples were trypsinzed with 0.05% trypsin-EDTA every 
week and the fibroblasts were washed off with PBS. Resulting mouse 
tumor cell lines were confirmed using PTEN genotyping (primers listed 
in Supplemental Table 2).
Real-time PCR
Total RNA was extracted from cells at 75%–90% confluency using RNeasy 
Mini Kit (QIAGEN) and was reverse transcribed using the ImProm-II 
Reverse Transcription System (Promega). Resulting cDNA was analyzed 
in triplicate using TaqMan 2X Universal PCR Master Mix (ABI). Relative 
mRNA concentrations were determined by 2–(Ct-Ct), where Ct is the mean 
and decrease cell stiffness. We demonstrate in an autochtho-
nous mouse model of metastatic melanoma that inactivation of 
Hif1α or Hif2α results in a significant reduction in metastases 
to regional lymph nodes, suggesting that these in vitro observa-
tions are operational in vivo (Figure 1F). This work defines 2 HIF 
target genes, PDGFRA and FAK, and is the first examination, to 
our knowledge, of the role of HIF2α in melanomagenesis. Impor-
tantly, our studies directly link hypoxia, HIF1α, and HIF2α to 
enhanced invadopodia formation, adding another pathologic 
stimulus to the list of those currently known to modify invado-
podia assembly and turnover. In aggregate, our studies define 
HIF1α and HIF2α as intimately involved in the process of metas-
tasis in malignant melanoma and further enforce the notion that 
the similarities between melanoma and RCC extend beyond mere 
clinical observations and rare germline genetic events.
Methods
Cell lines
Human melanoma cell lines SK Mel 24 and Sk Mel 28 were obtained from 
ATCC, RPMI 7951 was obtained from Lineberger Comprehensive Cancer 
Center Tissue Culture Facility (LCCC TCF), cell lines A375 and WM2664 
were a gift from Jack Arbiser (Emory University, Atlanta, Georgia, USA), 
and the UACC 257 cell line was a gift from Maria Soengas (Centro Nacio-
nal de Investigaciones Oncológicas, Madrid, Spain). Cells were cultured 
in either DMEM with the addition of 10% FBS (Benchmark FBS; Gemini 
Bio-Products) and penicillin/streptomycin (Gibco; Invitrogen) (A375SM, 
UACC 257, WM2664, Sk Mel 24, and Sk Mel 28) or αMEM with the addi-
tion of 10% FBS and penicillin/streptomycin (RPMI 7951). Cells were incu-
bated at 37°C under either normoxic (21% O2 and 5% CO2) or hypoxic 
(1% O2 and 5% CO2) conditions and medium was changed every other day.
siRNA transfections and shRNA transductions
shRNA constructs against HIF1α and HIF2α were obtained from the 
University of North Carolina (UNC) Lentiviral Core Facility (OpenBiosys-
tems). Sequences are listed in Supplemental Table 1. siRNA oligos against 
human HIF1α and HIF2α, FAK, and PDGFRα were purchased from ABI 
Technologies, and siRNA oligos against murine Hif1α and Hif2α were 
obtained from Dharmacon. siRNA transfections were performed using the 
Invitrogen Lipofectamine siRNAmax Kit according to the manufacturer’s 
instructions. Lentiviruses (pLKO) expressing shRNA against HIF1α and 
HIF2α were produced in 293T cells. Virus was collected after 72 hours and 
then placed on either A375 SM or WM2664 cells seeded at approximately 
70% confluency. Puromycin selections (A375 SM at 2 μg/ml, WM2664 at 
1 μg/ml) were performed starting at 48 hours.
Stable cell lines
Retroviruses (pBabe-puro) expressing stabilized versions of HIF1α or 
HIF2α were produced in 293T cells. Virus was collected after 72 hours and 
then placed on either A375 SM or WM2664 cells seeded at approximated 
70% confluency. Puromycin selections (A375 SM at 2 μg/ml, WM2664 at 
1 μg/ml) were performed starting at 48 hours.
Western blotting
Melanoma cell lines were grown to subconfluence in 10-cm dishes and lysed 
in buffer containing 200 mM Tris-HCl pH 8.0, 120 mM NaCl, and 0.5% 
NP-40 in the presence of protease (Roche) and phosphatase (Calbiochem) 
inhibitors. Whole-cell extracts (30 μg) were resolved by either 7.5% or 10% 
sodium dodecyl sulfate–polyacrylamide gel electrophoresis, transferred to 
a nitrocellulose membrane, and then probed with the specific antibodies 
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(Aperio). Digital images were stored and evaluated by the pathologist (C.R. 
Miller) within the Aperio Spectrum Database using the following scoring 
system: 0 = neg; 1+ = cytoplasmic staining; 2+ = weak nuclear staining; 
3+ = strong nuclear staining.
Statistics
Statistical analysis of percentage of living (Figure 1B) and tumor-free sur-
vival (Supplemental Figure 1D) were performed using a log-rank test. For the 
TMA studies (Figure 1, C and D), Wilcoxon rank-sum tests were used to com-
pare the expression between 2 groups. All statistical analyses were carried out 
in R (http://cran.r-project.org/). All other statistical comparisons were done 
using a 2-sided t test. A P value of less that 0.05 was considered significant.
Study approval
Mice were housed and treated in accordance with protocols approved by 
the IACUC for animal research at the University of North Carolina.
Acknowledgments
We would like to acknowledge the members of the Kim and 
Sharpless labs as well as Nicole Neel and Kim Monahan for use-
ful discussions and advice. We thank Carolyn Suitt of the Uni-
versity of North Carolina CGIBD Histology Core Facility, which 
is supported by the CGIBD Imaging and Histology Core (NIH 
P30-DK-034987). The authors thank the UNC TPL, which is 
supported, in part, by grants from the National Cancer Insti-
tute (3P30CA016086), the National Institute of Environmental 
Health Sciences (3P30ES010126), the Department of Defense 
(W81XWH-09-2-0042), and the UNC University Cancer Research 
Fund (UCRF). We would also like to thank the UNC Microscopy 
Services Laboratory Director, Robert Bagnell and the UNC Mouse 
Phase 1 Unit (MP1U). The SkinSPORE melanocytic tumor pro-
gression array was developed with the support of the Specialized 
Program of Research Excellence (IP50CA93683-03). This work 
was supported by the Melanoma Research Foundation (to W.Y. 
Kim), NIH R01 CA142794 (to W.Y. Kim), R33 CA155618 (to 
R. Superfine), U54 CA151652 (to W.Y. Kim and R. Superfine), 
NCI CA 122794, 166480, 163896, 140594, 141576, 120964, and 
154303 (to K. K. Wong), the University Cancer Research Fund 
(UCRF), and Department of Defense grants PC094631 and 
W81XWH-08-1-0064 (to W.Y. Kim). W.Y. Kim is a Damon Runyon 
Merck Clinical Investigator.
Received for publication September 12, 2012, and accepted in 
revised form February 8, 2013.
Address correspondence to: William Y. Kim, Lineberger Com-
prehensive Cancer Center, University of North Carolina, CB# 
7295, Chapel Hill, North Carolina 27599-7295, USA. Phone: 
919.966.4765; Fax: 919.966.8212; E-mail: wykim@med.unc.edu.
threshold cycle difference after normalizing to 18S values. Primers used 
for PCR were purchased from ABI Technologies.
Experimental lung metastasis assay
A375 SM cells stably transduced with shRNA constructs against either 
HIF1α, HIF2α, or a nonspecific control were harvested by brief exposure to 
0.05% trypsin EDTA solutions (Gibco; Invitrogen). Cells were washed and 
resuspended in Ca2+- and Mg2+-free HBSS (Gibco; Invitrogen). A total of 
5 × 105 cells in 0.2 ml of HBSS were injected into the lateral vein of nude mice. 
Eight weeks later, the animals were sacrificed and the lungs were removed, 
washed in PBS (Cellgro), and fixed in 10% buffered formalin solution 
(Sigma-Aldrich) overnight to facilitate counting of surface tumor nodules.
Magnetic tweezers assay
Cultures of A375 SM cells were plated on collagen-coated glass coverslips 
and grown to 50%–80% confluence; 4.5 μm tosylactivated magnetic beads 
(Invitrogen) were conjugated with human fibronectin and incubated with 
the cells for 10 minutes. The 3D force microscope system was used to apply 
50–100 pN of force to each bead for 5 seconds, and the resultant motion 
and recovery were recorded at 30 frames per second. Cells were used for as 
many separate fields of view as could be recorded within 1 hour. Bead posi-
tion was analyzed using Video Spot Tracker software (http://cismm.cs.unc.
edu) and fit to a Jeffrey’s model for stiffness, as described previously (33).
TMA
Antibodies and immunohistochemistry. Rabbit polyclonal anti-HIF1α and 
anti-HIF2α antibodies were from Novus Biologicals and Eton Biosci-
ence Inc., respectively.
IHC was carried out in the Bond Autostainer (Leica Microsystems Inc.). 
Slides were dewaxed in Bond Dewax solution (AR9222) and hydrated 
in Bond Wash solution (AR9590). Antigen retrieval for both antibodies 
was performed at 100°C in Bond-Epitope Retrieval Solution 1, pH–6.0, 
(AR9961) for 30 minutes for HIF1α and 40 minutes for HIF2α. Detec-
tion was performed using Bond Polymer Refine Red Detection (DS9390). 
Stained slides were dehydrated and coverslipped. Positive and negative con-
trols (no primary antibody) were included for each antibody.
TMA construction. The previously described nevus to melanoma progres-
sion TMA (41) was used to stain for HIF1α and HIF2α. In addition, mela-
noma cases metastatic to brain, lung, and liver were obtained from UNC 
Hospital’s surgical pathology archive to construct the UNC TMA 69A1 
(UNC IRB-approved protocol 08-0242). H&E-stained slides of the selected 
cases were reviewed by a surgical pathologist (C.R. Miller), and representa-
tive areas of tumor and adjacent normal tissues were circled for coring. 
TMA block containing triplicate cores (0.6 mm) of melanoma metastases 
was constructed. TMA was cut into 4-micron–thick sections and placed on 
positively charged glass slides.
Digital imaging and image analysis. Stained TMAs were digitally imaged at 
×20 magnification using the Aperio ScanScope XT (Aperio Technologies). 
TMA slides were de-arrayed to visualize individual cores, using TMA Lab 
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